Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
Supernus Pharmaceuticals and Indivior Pharmaceuticals have signed an all-stock merger agreement to establish a new company focused on CNS diseases.
The combined company, which will …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven
Supernus, Indivior merge to create CNS-focused company and expand BD opportunities
Supernus, Individor merge to beef up brain drug portfolio
This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108%
Drug giants AstraZeneca, BMS weighing $400 bn tie-up | Euractiv
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster…
After partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a…
Opioid addiction has cast a shadow over the U.S. But pharma stock Indivior Pharmaceuticals is eyeing a fresh entry as profits…
Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to the stock's last close.
